Retrospective Study on the Evolution of CIN 1 to 3 in Per and Postpartum in Nancy From 2014 to 2022
NCT ID: NCT05595252
Last Updated: 2022-10-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2014-01-01
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Pregnant patients are most of the time young and are part of the target population for screening, and for many women, it is the first encounter with a gynecologist.
The cervical smear is therefore an important step of the first consultation during pregnancy In the case of pathological results, colposcopies with biopsies are performed, frequently finding CIN 1 to 3. (cervical intraepithelial neoplasia) These CIN lesions evolve slowly and most of the time, treatment can be withheld until the end of the pregnancy.
Several studies suggest a higher regression rate in pregnant patients. Our study will evaluate the rate of regression, progression or persistence of these lesions in per and post partum patients in Nancy, between 2014 and 2022.
To obtain our results, we will compare the results of per and post partum biopsies in each patient.
In a second step, we will study the risk factors of aggravation or on the contrary the protective factors, allowing a faster regression of the lesions
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Self-sampling and Human Papillomavirus (HPV)-Testing for Unscreened Women in Cervical Cancer Prevention
NCT01014026
Evaluation of Initial High Risk Human Papillomavirus (HR-HPV) Viral Load as Predictive Marker for Cervical Intraepithelial Neoplasia Grade 1 (CIN1) Persistence
NCT00682552
Longitudinal HPV Pap in CIN and VAIN
NCT05931354
Evaluation of First-void Urine as an Alternative to Cervical Sampling for Human Papillomavirus (HPV) Testing in Cervical Cancer Screening (Single-center Study).
NCT06254846
Evaluation of the Satisfaction of Patients With Conization Under Local Anesthesia
NCT03157752
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with CIN lésions during pregnancy
cervical biopsy
cervical biopsy made during and after pregancy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
cervical biopsy
cervical biopsy made during and after pregancy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* in Nancy, France, MRUN Center
* between 2014 and 2022
Exclusion Criteria
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central Hospital, Nancy, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
MARTIN Elena
Assistant clinical Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Camille BENOIT
Role: PRINCIPAL_INVESTIGATOR
CHRU Nancy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
BENOIT Camille
Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022PI157/EUDRACT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.